What's New in CLL?
ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With Venetoclax ± Rituximab in R/R CLL - Updated BRUIN Study Results Including MRD Data"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Nirav Shah
By
Insights from 2023 ASH Annual Meeting
FEATURING
Nirav Shah
Login to view comments.
Click here to Login
What's New in CLL?